Background Shares in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) climbed as much as +31% on February 12th following a report from Reuters citing anonymous sources …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, …
Holiday sales, pipeline updates, and a tax credit extension mark this week’s earnings reports from Fitbit Inc (NYSE:FIT), First Solar, Inc. (NASDAQ:FSLR), Intercept …
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that …
The New Year brings another turbulent season for biotech investors as top-line data continues to be released and the FDA’s approval process marches …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic, underserved liver diseases, …
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, …
The biotechnology sector is very fast-paced as every event, such as new data, FDA decisions, and trial initiations can double or deplete a …
Never a dull moment in the volatile biotechnology sector as analysts remain bullish on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) as the company prepares to …
